Research Topics
Genomes and Genes | Brett S CarverSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumorsBrett S Carver
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, 353 E 68th St, New York, NY 10021, USA
J Clin Oncol 25:5603-8. 2007..We evaluated men undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for NSGCT to determine associations between year of treatment and clinical outcome...
Feasibility study of a clinically-integrated randomized trial of modifications to radical prostatectomyAndrew J Vickers
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 11215, USA
Trials 13:23. 2012..We aimed to determine the feasibility of implementing such a trial for radical prostatectomy...- Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissectionBrett S Carver
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Urol 176:100-3; discussion 103-4. 2006..We evaluated patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell tumors to determine predictors of teratomatous elements in the retroperitoneum... 
The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancerBrett S Carver
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Urology 75:1431-5. 2010..After the multidisciplinary management of metastatic germ cell tumor, approximately 10%-15% of patients with the histologic finding of fibrosis or teratoma will suffer disease recurrence...- Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapyBrett S Carver
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
BJU Int 95:509-12. 2005.... - Race is not a predictor of prostate cancer detection on repeat prostate biopsyBrett S Carver
Department of Urology, Louisiana State University Health Sciences Center and Overton Brooks Veterans Administration Medical Center, Shreveport, Louisiana, USA
J Urol 172:1853-5. 2004..We evaluated men undergoing repeat prostate biopsies for persistently increased serum prostate specific antigen (PSA) levels to determine if race was a predictor of cancer detection... - Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissectionBrett S Carver
Department of Urology and Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 25:4365-9. 2007..We evaluated our experience with PC-RPLND to determine the incidence of disease extending outside the boundaries of a modified PC-RPLND... - Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratomaBrett S Carver
Department of Urology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 25:1033-7. 2007..We evaluated patients at our institution undergoing initial PC-RPLND for teratoma to determine their clinical outcome... - Management of post-chemotherapy extra-retroperitoneal residual massesBrett S Carver
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
World J Urol 27:489-92. 2009..While the retroperitoneum is often the first and only site of metastatic disease, approximately 40% of patients presenting with metastatic disease will have disease involving extra-retroperitoneal sites... - Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancerTimothy A Masterson
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Urology 79:156-9. 2012..We reviewed our institutional experience in patients undergoing resection of extraretroperitoneal (ERP) residual masses after chemotherapy to assess its impact on cancer progression and survival... - Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumourBobby Shayegan
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
BJU Int 99:993-7. 2007.... - Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease siteTimothy A Masterson
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Urology 79:1079-84. 2012..To compare the survival outcomes of patients with advanced nonseminoma and extraretroperitoneal (ERP) disease observed for a clinical complete response (CCR) with those demonstrating a pathologic complete response (PCR)... - Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methodsOfer Yossepowitch
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 178:493-9; discussion 499. 2007..Of patients undergoing radical prostatectomy we identified those at high risk based on 8 previously described definitions. We examined pathological characteristics and prostate specific antigen outcomes... - Clinical outcome and predictors of survival in late relapse of germ cell tumorDavid S Sharp
Department of Urology, Memorial Sloan Kettering Cancer Center, 353 E 68th St, New York, NY 10021, USA
J Clin Oncol 26:5524-9. 2008..Late relapse (LR) of germ cell tumor (GCT) is a well recognized entity associated with poor survival. We report on our experience with LR and determine predictors of survival... - Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissectionR Houston Thompson
Department of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Urology 79:361-4. 2012..Lymph node counts are a proposed measure of quality assurance for numerous malignancies. Investigation of patient factors associated with lymph node counts are lacking... - The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumorAtreya Dash
Department of Urology and Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 112:800-5. 2008..The objectives of the current study were to determine the clinical outcome, patterns of relapse, and incidence of teratoma in the retroperitoneum for men with cIS NSGCT... - Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomyOfer Yossepowitch
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Eur Urol 53:950-9. 2008..We assessed how accurately these definitions identify patients likely to receive secondary cancer therapy, experience metastatic progression, or die of prostate cancer... - MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitorsNicola J Clegg
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
PLoS ONE 6:e17449. 2011..Since increased MYC expression is an early feature of many human prostate cancers, these data have implications for treatment of human prostate cancers with PI3K-pathway alterations using mTOR inhibitors... - Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumorsScott E Eggener
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 109:528-35. 2007..The authors assessed their institutional experience of retroperitoneal lymph node dissection (RPLND) after multiple chemotherapy regimens for advanced GCT... - Contemporary lymph node counts during primary retroperitoneal lymph node dissectionR Houston Thompson
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Urology 77:368-72. 2011..We report our contemporary single-surgeon experience with lymph node counts during primary RPLND for nonseminomatous germ cell tumors... - Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancerScott E Eggener
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 177:937-42; discussion 942-3. 2007..We evaluated the incidence, sites and histology of disease outside 5 modified retroperitoneal lymph node dissection templates for patients with low stage nonseminomatous germ cell tumors of the testis... - African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogramBrent V Yanke
State University of New York Downstate Medical Center, New York, NY, USA
BJU Int 98:783-7. 2006..This nomogram is the first to individualise the risk by AA or Caucasian race in a predictive model for counselling men on their probability of having cancer at the time of their first biopsy... - Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancerBrett S Carver
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer Cell 19:575-86. 2011.... - ETS rearrangements and prostate cancer initiationBrett S Carver
Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Nature 457:E1; discussion E2-3. 2009..To this end, we demonstrate that the prostate-specific overexpression of ERG does not initiate prostate tumorigenesis... - Evaluation of lymph node counts in primary retroperitoneal lymph node dissectionR Houston Thompson
Department of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Cancer 116:5243-50. 2010..Lymph node counts are a measure of quality assurance and are associated with prognosis for numerous malignancies. To date, investigations of lymph node counts in testis cancer are lacking... - Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancerBrett S Carver
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 176:564-8. 2006..In our series neoadjuvant hormonal therapy offered no advantage with respect to disease recurrence. Radical prostatectomy remains an integral component in the treatment of select patients with clinical stage T3 prostate cancer... - Retroperitoneal histologic findings of patients with elevated serum alpha-fetoprotein and pure seminoma at orchiectomyShilajit D Kundu
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Urology 78:844-7. 2011..These patients underwent treatment on the assumption that the lesion was nonseminomatous germ cell tumor (NSGCT)... - Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumourTimothy A Masterson
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
BJU Int 110:950-5. 2012..Our results showed similar clinical and pathological characteristics, and survival outcomes that compare favourably with those of men aged <50 years... - Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mLCaleb B Bozeman
Department of Urology, Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana 71130, USA
Urology 66:803-7. 2005..To evaluate men with abnormal digital rectal examination (DRE) findings and a serum prostate-specific antigen (PSA) level less than 4.0 ng/mL who underwent prostate biopsy... - Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostateBrett S Carver
Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, New York, USA
Nat Genet 41:619-24. 2009..Thus, ERG has a distinct role in prostate cancer progression and cooperates with PTEN haploinsufficiency to promote progression of HGPIN to invasive adenocarcinoma... - Integrative genomic profiling of human prostate cancerBarry S Taylor
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Cancer Cell 18:11-22. 2010..The genomic and clinical outcome data from these patients are now made available as a public resource... - Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancerJoseph A Pettus
Department of Surgery, Division of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Urology 73:328-31; discussion 331-2. 2009..To evaluate the clinical parameters associated with the recovery of ejaculation after nerve-sparing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for nonseminomatous germ cell tumor... - Squamous cell carcinoma of the penis: a retrospective review of forty-five patients in northwest LouisianaBrett S Carver
Department of Urology, Louisiana State University Health Science Center, Shreveport 71130, USA
South Med J 95:822-5. 2002..3% of malignancies in men seen at our institution. Nodal metastasis was a poor prognostic indicator. Although local penile recurrence was rare (8.8%), patients should be counseled on the importance of self-examination... - Late relapse of testicular germ cell tumorsBrett S Carver
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Urol Oncol 23:441-5. 2005..In this review, we present the recent data regarding the clinical presentation, patterns of relapse, histologic findings, appropriate treatment options, and outcomes for men with late relapse of germ cell tumors... - Impact of positive surgical margins in patients undergoing partial nephrectomy for renal cortical tumoursEric O Kwon
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
BJU Int 99:286-9. 2007.... - The current status of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ-cell tumorsBrett S Carver
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, USA
Nat Clin Pract Urol 2:330-5. 2005..Future prospective internal review board-approved trials need to be developed to evaluate the therapeutic efficacy of laparoscopic RPLND, with careful observation of patients with pathologic low-volume nodal disease... - Do concerns about more advanced pathological features increase the likelihood of neurovascular bundle resection in black men undergoing radical prostatectomy?Brett S Carver
Department of Urology, Louisiana State University Health Sciences Center and Overton Brooks Veterans Administration Medical Center, Shreveport, USA
J Urol 171:700-2. 2004.... - The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigenBrett S Carver
Department of Urology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA
J Urol 169:589-91. 2003..2%) among men in the general population who present for prostate cancer screening and appears to contribute to increased serum PSA levels in some men... - Germ cell tumors of the testisBrett S Carver
Department of Urology, Memorial Sloan-Kettering Cancer Center, 353 East 68th Street, New York 10021, USA
Ann Surg Oncol 12:871-80. 2005..This review summarizes the principal management of germ cell tumors of the testis, highlighting the indications for surgery, controversies surrounding the integration of surgery, and alternative management strategies... - Adult and pediatric testicular teratomaBrett S Carver
Department of Urology and Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Urol Clin North Am 34:245-51; abstract x. 2007.... - Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesisJennifer C King
Memorial Sloan Kettering Cancer Center, New York, New York, USA
Nat Genet 41:524-6. 2009..TMPRSS2-ERG-positive human tumors are also enriched for PTEN loss, suggesting cooperation in prostate tumorigenesis... - Postchemotherapy surgery for germ cell tumors of the testisBrett S Carver
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Curr Opin Oncol 23:271-4. 2011..To summarize the surgical management of metastatic germ cell tumors of the testis, highlighting the indications for surgery and controversies surrounding the integration of surgery... - Treatment of chronic prostatitis lowers serum prostate specific antigenCaleb B Bozeman
Department of Urology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA
J Urol 167:1723-6. 2002..Our study suggests that chronic prostatitis is an important cause of elevated PSA and when it is identified, treatment can decrease the percent of negative biopsies... - Large granular cell tumor of the penis in a 53-year-old man with coexisting prostate cancerBrett S Carver
Department of Urology, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71130, USA
Urology 59:602. 2002..Thus far, only 7 cases of granular cell tumor of the penis have been reported. We report a case of granular cell tumor of the penis in a man undergoing radical retropubic prostatectomy for organ-confined adenocarcinoma of the prostate... - Ureteral injury due to penetrating traumaBrett S Carver
Department of Urology, Louisiana State University Health Sciences Center, Shreveport, LA, USA
South Med J 97:462-4. 2004..We sought to evaluate the diagnosis and management of penetrating ureteral injuries at our trauma center... - Ubiquitination regulates PTEN nuclear import and tumor suppressionLloyd C Trotman
Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cell 128:141-56. 2007.... - Mouse modeling in oncologic preclinical and translational researchBrett S Carver
Cancer Biology and Genetics Program and Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 12:5305-11. 2006..Ultimately this will translate from preclinical mouse model trials to the development of clinical trials and protocols for cancer patients. Here we review the usefulness of mouse modeling in oncologic translational research... - Surgery for retroperitoneal relapse in the setting of a prior retroperitoneal lymph node dissection for germ cell tumorGeoffrey T Gotto
Department of Urology, Memorial Sloan Kettering Cancer Center, Weill College of Medicine, New York, USA
Indian J Urol 26:102-7. 2010..Patients with retroperitoneal relapse following initial RPLND should be treated with reoperative RPLND and chemotherapy and can expect long term survival rates nearing 70% when treated in tertiary centers by experienced surgeons...